BRIEF published on 12/11/2025 at 07:05, 11 months 6 days ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
PRESS RELEASE published on 12/11/2025 at 07:00, 11 months 6 days ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 1 year ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
BRIEF published on 11/10/2025 at 07:05, 1 year ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
PRESS RELEASE published on 11/10/2025 at 07:00, 1 year ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 1 year ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 1 year ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 1 year ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 1 year ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
BRIEF published on 11/05/2025 at 07:05, 1 year ago BioVersys présentera ses travaux lors de la conférence annuelle Stifel 2025 sur les soins de santé. New York Conférence Sur Les Soins De Santé BioVersys Développements Cliniques Bactéries Multirésistantes
Published on 11/17/2026 at 23:00, 14 minutes ago Alset AI Ventures Inc. Announces Extension of Annual General Meeting Deadline
Published on 11/17/2026 at 21:30, 1 hour 44 minutes ago Fairplay Ventures INC. Announces Filing of Filing Statement in Connection With Qualifying Transaction
Published on 11/17/2026 at 15:00, 8 hours 14 minutes ago Secure Blockchain's Agentic Solutions Signs Engineering Company, Expanding Enterprise AI Into Heavy Industry
Published on 11/17/2026 at 14:45, 8 hours 29 minutes ago NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)
Published on 11/17/2026 at 14:00, 9 hours 14 minutes ago FaZe Esports, a GameSquare Company, Wins Rainbow Six Championship at Osaka Major
Published on 11/17/2026 at 22:00, 1 hour 14 minutes ago Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 11/17/2026 at 21:12, 2 hours 2 minutes ago EQS-Adhoc: JDC Group AG: Adjustment of Full-Year Guidance
Published on 11/17/2026 at 20:21, 2 hours 53 minutes ago Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 11/17/2026 at 20:00, 3 hours 14 minutes ago EQS-Adhoc: Sasol Financing USA LLC: SASOL ANNOUNCES RESULTS OF THE INVITATION TO REPURCHASE OUTSTANDING US$750 MILLION 4.5% GUARANTEED SENIOR UNSECURED CONVERTIBLE BONDS DUE 2027
Published on 11/17/2026 at 19:41, 3 hours 33 minutes ago SMAG Mobile Antenna Masts AG Management Board revises forecast for fiscal year 2026; strong confidence for 2027
Published on 11/17/2026 at 18:00, 5 hours 14 minutes ago 20261117 - Accor - Accor to increase its stake in Ennismore
Published on 11/17/2026 at 18:00, 5 hours 14 minutes ago Accor - Accor se renforce au capital de Ennismore
Published on 11/17/2026 at 17:45, 5 hours 29 minutes ago EURAZEO COMPLETES THE SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT ALONGSIDE PARTNERS GROUP
Published on 11/17/2026 at 17:45, 5 hours 29 minutes ago EURAZEO FINALISE LA CESSION DE SA PARTICIPATION DANS AROMA-ZONE ET SON REINVESTISSEMENT AUX COTES DE PARTNERS GROUP
Published on 11/17/2026 at 07:40, 15 hours 34 minutes ago SUEZ INTERNATIONAL SAS COMPLETES THE SALE OF C.10.65 MILLION SHARES OF ACEA S.P.A.